Avraham Eisbruch

Avraham Eisbruch, MD

Professor
Newman Family Professor

UH B2C490
1500 E Med Ctr Dr
Ann Arbor MI 48109

734-936-4300

Clinical Contacts

734-936-4300

Administrative Contact

Kelley Forbes 734-232-5244

Biography

Dr. Eisbruch has led many investigations and published over 200 peer-reviewed papers involving chemo-irradiation combinations for head and neck cancer and the characteristics of the toxicity of therapy. He has also investigated and developed methods to reduce toxicity using physiologic and metabolic imaging in treatment planning, prognosis, and therapy assessment, and assessing the uncertainties related to and value of therapy adaptation. He was the principal investigator of the first RTOG IMRT study, 00-22.

Dr. Eisbruch's most recent research includes using functional MRI to guide RT intensification for poor prognosis head and neck patients, funded by the NIH. 

Areas of Interest

  • Characterizing the toxicity of therapy of head and neck cancers and methods to reduce it by IMRT
  • Improving delineation of targets and normal organs, using physiologic and metabolic imaging in treatment planning, prognosis, and therapy assessment
  • Assessing the uncertainties related to and value of therapy adaptation in head and neck cancer 

Clinical Interests

  • Chemo-radiotherapy of head and neck cancer

Honors & Awards

National and International

2014   Fellow of the American Society for Radiation Oncology (FASTRO)
2012   The 2012 Annual Visiting Professorship, Department of Radiation Oncology, Stanford University, Palo Alto, CA
2010   Wharton Lecturer. Princess Margaret Hospital, University of Toronto, Toronto, Canada          
2009   Honorary Membership, British Association of Head & Neck Oncologists
2009   Blair Hesketh Memorial Lecturer.  British Association of Head & Neck Oncologists.
2008   American Head &Neck Society Presidential Citation “For outstanding leadership and contributions in radiation oncology and QOL of patients with advanced head and neck cancer”. Conferred at the 7th International Conference on Head and Neck Cancer, San Francisco CA.
2015   Newsweek Top Cancer Doctors
2003 2001   Castle Connolly “Best Doctors in America”
2011-2014  US News and World Report Top Doctors (top 1% in the specialty in the nation)

Institutional

2015      Outstanding Clinician Award. Medical School, University of Michigan
2014      Inductee, League of Research Excellence. Medical School, University of Michigan

1996 -1997, 2005, 2008  Teacher of the Year. Nominated by the residents of the Department of Radiation Oncology, University of Michigan.
2001, 2006, 2013 Teacher of the Year. Nominated by  the Association of Residents in Radiation Oncology (ARRO).
2004  “Token of Appreciation from Medical Students” Award.

Credentials

  • MD, Sackler School of Medicine, Tel Aviv University, 1978
  • Board Certification: Radiation Oncology    

Grants

  • 1RO1CA184153-01A1, (PI:Eisbruch), 12/2014-11/2019, National Institutes of Health,  Adaptive therapy of advanced head and neck cancer, Role: Principal Investigator. 
  • U01 CA183848 (PIs: Eisbruch/Cao)  6/4/2014-5/31/2019, National Institutes of Health, Quantitative MRI models of HN Cancers for Physiological Adaption of RT Role: Co-Principal Investigator.
  • (PI:Eisbruch), Discovery Fund of the University of Michigan Rogel Cancer Center, Randomized study of Functional MRI to direct therapy of poor-prognosis head and neck cancer,  Role: Principal Investigator. 

Published Articles via PubMed

Published Articles or Reviews

Selected from over 240 publications

  • Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Ang KK. Multi-institutional trial of accelerated hypofractionated IMRT for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 76;1333-8, 2010.
  • Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol. 19:792-9, 2001.
  • Eisbruch A, Kim HM, Ten Haken R, Marsh L, Ship JA.  Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 45:577-587, 1999.
  • Eisbruch A,  Schwartz M, Rasch C, Vineberg M, Damen E, Van As CJ, Marsh R,  Pameijer FA, Balm AJM.  Dysphagia and aspiration following chemo-irradiation of head and neck cancer: which anatomical structures are affected, and can they be spared by IMRT?  Int J Radiat Oncol Biol Phys. 60:1425-39. 2004.
  • Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A.  Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.  J Clin Oncol.  28(16):2732-8. 2010, PMC2881852.
  • Vainshtein J, Moon D, Feng FY, Chepeha DB, Stenmark MH, Eisbruch A. Long-term quality of life after chemo IMRT for locally advanced HPV-positive oropharyngeal cancer: Prospective longitudinal study. Int J Radiat Oncol Biol Phys. 91(5):925-33, 2015.
  • Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T, Bradford C, Mukherji SK, Eisbruch A.  Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study.  Int J Radiat Oncol Biol Phys. 72(5):1287-90, 2008. PMC3638953

Web Sites

Locations

1500 E Medical Center Dr
Ann Arbor, MI 48109-5010

734-936-4320